46results about How to "Enhance humoral immune response" patented technology

The invention provides adjuvants, immunogenic compositions, and methods useful for polynucleotide-based vaccination and immune response. In particular, the invention provides an adjuvant of cytofectin:co-lipid mixture wherein cytofectin is GAP-DMORIE.

The invention provides methods for increasing or decreasing antibody production in vivo by inhibiting or promoting the activity of fibroblast growth factor-2 (FGF2) respectively.

The invention belongs to the technical field of biological pharmacy, and discloses a pseudomonas aeruginosa gene engineering vaccine candidate antigen PA5505 purification method. A DNA (deoxyribonucleic acid) sequence for encoding PA5505 protein activity function fragment is cloned to a pGEX-6p-2 vector by a gene engineering technology, escherichia coli recombinant bacteria pGEX-6p-2-PA5505 / XL-1 blue are built, and PA5505 proteins are acquired by inducible expression. Gene engineering bacteria expressing PA5505 are subjected to technologies such as high-pressure bacteria breaking, GST affinitychromatography, PP enzyme digestion, SP HP chromatography and Q HP chromatography to obtain high-purity vaccine candidate antigen PA5505. The purification method is simple in purification process, easy to amplify and good in repeatability, the acquired target proteins are high in purity, and animal experiments prove that a body can be effectively stimulated to generate high humoral immune response and good immune protection functions.

The invention provides a neopterin adjuvant and a vaccine containing the neopterin adjuvant, and belongs to the technical field of immunology. According to the vaccine containing the neopterin adjuvant, each single vaccine contains 0.5-1 microgram of the neopterin adjuvant. The neopterin adjuvant belongs to an endogenous substance in the human body, is small in toxic and side effects, is safe and reliable when used in an immunizing dose range, and can effectively induce antigenic specificity humoral immune responses, and the induced humoral immune response effect is better than that of a group without adjuvants and similar to that of a group with an aluminum adjuvant. Raw materials of the neopterin adjuvant are easy to obtain, the neopterin adjuvant is a commercially available product and low in cost and can be added to multiple traditional vaccines and genetic engineering vaccines to be used as a vaccine adjuvant.

The invention discloses a co-immune vaccine for prevention and / or treatment of diseases caused by respiratory syncytial virus infection. The vaccine is composed of a DNA vaccine and a subunit vaccine. The DNA vaccine is a recombinant expression vector containing an encoding gene of a protein as shown in a sequence 2 in a sequence table. The subunit vaccine is a protein as shown in the sequence 2 in the sequence table. Experimental results show that the co-immune vaccine provided by the present invention can enhance the humoral immune response of immune animals, also inhibit too strong cellular immune response, effectively inhibit inflammation, protect lung tissues of mammalians and prevent function from destruction of RSV infection.

The invention discloses a metal aluminum nano adjuvant, a preparation method thereof, a vaccine composition of the vaccine composition and an application of a metal aluminum nano particle. The vaccine adjuvant comprises the metal aluminum nano particle, and can be used as a candidate adjuvant of preventive vaccines and therapeutic vaccines for various diseases such as infection, autoimmune diseases and tumors. The vaccine adjuvant provided by the invention is combined with an antigen for use, so that humoral immune response and cellular immune response of the vaccine can be effectively enhanced, and the enhancement effect of the vaccine adjuvant is remarkably superior to that of a commercially available aluminum hydroxide adjuvant.

The present invention discloses an application of ginseng total saponin or monomer saponin Rb1 as vaccine immunologic adjuvant. The ginseng total saponin or monomer saponin Rb1 and aluminium hydroxide are mixed and used as vaccine immunologic adjuvant, and as compared with traditional aluminium hydroxide adjuvant said invention possesses the following advantages: (1) its side effect is less; (2) said vaccine can be stored under the condition of frozen low-temp. and it can prolong effective period of vaccine; (3) its method is simple and convenient, its quality is easy to be controlled; and (4) it can induce body to produce higher humoral immunity response.

Provided are an Ebola virus envelope glycoprotein (that is GP protein) codon optimized nucleotide sequence, a human replication deficient recombinant adenovirus capable of expressing the nucleotide sequence, and applications in preparing a vaccine for preventing Ebola virus diseases. The nucleotide sequence takes a replication deficient 5 type adenovirus that is lack of E1 and E3 in a combined mode as a vector. HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and carried protective antigenic genes are codon optimized Zaire type Ebola virus Makona strain envelope glycoprotein genes. After the envelope glycoprotein genes are optimized by codon, the expression level in transfection cells is obviously improved.

The invention relates to a composite adjuvant, a vaccine comprising the same and a preparation method of the vaccine. The composite adjuvant comprises a noncompetitive inhibitor of indoleamine-2,3 dioxygenase and aluminum salts, the noncompetitive inhibitor of the indoleamine-2,3 dioxygenase is 4-benzimidazole, the content of the 4-benzimidazole is 0.5-1.5 mg, the aluminum salts are aluminium hydroxide, and the content of the aluminium hydroxide is 300 mu g. The invention further relates to the vaccine comprising the composite adjuvant and a preparation method of vaccine. The raw materials of the composite adjuvant are easy to obtain, a preparation process of the vaccine is simple, the cost is low, the performance is stable, toxic and side effects are small, immune response is promoted jointly from the positive aspect and the negative aspect of organism immunoregulation, the composite adjuvant is safe and reliable when used in a range of immunizing dose, humoral immune response of antigenic specificity can be induced effectively, humoral immune responses of the antigenic specificity are enhanced remarkably, and the effect of the composite adjuvant is higher than the effects of a group without adjuvant, a group with a single adjuvant and a group with an aluminum adjuvant.

The invention belongs to the field of biotechnology, and relates to a MntC recombinant protein of staphylococcus aureus (SA), a carrier comprising the recombinant protein, a host, a composition or a kit, application, preparation, fermentation and purification method of the protein. The MntC recombinant protein prepared by the method has strong immunogenicity, is safe and non-toxic, and is proved by animal tests to be able to effectively stimulate an organism to generate high efficient humoral immune response and good immune protection.

The invention discloses a respiratory syncytial virus vaccine, and a preparation method and an application thereof. The active components of the respiratory syncytial virus vaccine comprise a respiratory syncytial virus G protein and an immunosuppressant; the amino acid sequence of the respiratory syncytial virus G protein is represented by sequence 2 in a sequence table; and the immunosuppressant is cyclosporins A. Test proves that the respiratory syncytial virus vaccine can enhance the humoral immunoreaction in the virus neutralizing antibody level of immune animals, can inhibit too strong cellular immunity reactions, effectively and specifically inhibits inflammation related pathological reactions, and has the advantages of manure technology, low cost, no side effects and easy promotion.

The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice. Cationic amphiphiles with mannose-mimicking shikimoyl head-groups described in the present invention are likely to find future applications in the field of genetic immunization.

The invention belongs to the technical field of biopharmaceuticals, and discloses a method for purifying Pseudomonas aeruginosa genetic engineering vaccine candidate antigen PA5505, in which the DNA sequence encoding the active functional fragment of the PA5505 protein is cloned onto the pGEX‑6p‑2 carrier through genetic engineering technology , construct the Escherichia coli recombinant engineering strain pGEX‑6p‑2‑PA5505 / XL‑1 blue, and obtain the PA5505 protein by inducing expression. In the present invention, high-purity vaccine candidate antigen PA5505 is obtained by performing high-pressure bacteriostasis, GST affinity chromatography, PP enzyme digestion, SP HP chromatography, Q HP chromatography and other technologies on genetically engineered bacteria expressing PA5505. The purification process of the invention is simple, easy to scale up, and has good repeatability, and the obtained target protein has high purity. Animal experiments have proved that it can effectively stimulate the body to produce a higher humoral immune response and good immune protection.

The invention relates to a composite adjuvant, a vaccine comprising the same and a preparation method of the vaccine. The composite adjuvant comprises a noncompetitive inhibitor of indoleamine-2,3 dioxygenase and aluminum salts, the noncompetitive inhibitor of the indoleamine-2,3 dioxygenase is 4-benzimidazole, the content of the 4-benzimidazole is 0.5-1.5 mg, the aluminum salts are aluminium hydroxide, and the content of the aluminium hydroxide is 300 mu g. The invention further relates to the vaccine comprising the composite adjuvant and a preparation method of vaccine. The raw materials of the composite adjuvant are easy to obtain, a preparation process of the vaccine is simple, the cost is low, the performance is stable, toxic and side effects are small, immune response is promoted jointly from the positive aspect and the negative aspect of organism immunoregulation, the composite adjuvant is safe and reliable when used in a range of immunizing dose, humoral immune response of antigenic specificity can be induced effectively, humoral immune responses of the antigenic specificity are enhanced remarkably, and the effect of the composite adjuvant is higher than the effects of a group without adjuvant, a group with a single adjuvant and a group with an aluminum adjuvant.

The invention provides a newcastle disease live vaccine adjuvant. The newcastle disease live vaccine adjuvant comprises the following raw materials in percentage by weight: 60-75% of a buffer solution, 5%-10% of squalane, 5%-10% of squalene, 3%-5% of pluronic, 1%-3% of an emulsifier, 2%-4% of hydroxymethyl cellulose, 2%-4% of dimethyl dioctadecyl ammonium bromide and 1%-3% of polycaprolactone. Theadjuvant composition can remarkably improve humoral immune response and cellular immune response of the newcastle disease vaccine, not only can generate a relatively high antibody level in a short time, but also can stimulate an organism to generate efficient protective force for a long time, when the adjuvant composition is used for preparing vaccines, large emulsification equipment is not needed, the vaccine preparation process is stable, and the side reaction after vaccine immunization is small.

The present invention relates to an immunoadjuvant composition comprising at least adjuvant and at least one MyD88-dependent pathway agonist.

An altered avian NDV that contains the coding sequence of avian interleukin-4 (IL-4), or a portion thereof, in the reverse orientation suppresses in-ovo IL-4 production via RNAi when administered to embryonic birds. An immunogenic composition containing this altered NDV is included in this invention. The altered avian NDV can, optionally contain a polynucleotide encoding a heterologous antigen from a heterologous avian pathogen and can produce said heterologous antigen in-ovo.